1. Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
- Author
-
Dai Koguchi, Kazumasa Matsumoto, Masaomi Ikeda, Yuriko Shimizu, Marie Nakamura, Yutaka Shiono, Hiroki Katsumata, Yuichi Sato, and Masatsugu Iwamura
- Subjects
Carcinoma, Transitional Cell ,Biological Products ,Paclitaxel ,Organic Chemistry ,General Medicine ,Gemcitabine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Phosphoglycerate Kinase ,Antineoplastic Combined Chemotherapy Protocols ,cancer of the urinary tract ,gemcitabine ,paclitaxel ,survival ,biomarkers ,Humans ,Physical and Theoretical Chemistry ,Cisplatin ,Molecular Biology ,Immune Checkpoint Inhibitors ,Spectroscopy ,Retrospective Studies ,Platinum - Abstract
An investigation of alternatives to immune checkpoint inhibitors for advanced urothelial cancer (aUC), with biologic information, is urgently needed. Clinical data for 53 patients who received gemcitabine–paclitaxel therapy (GP) as 2nd-line chemotherapy for aUC refractory to platinum-based chemotherapy were retrospectively reviewed. The efficacy and tolerability of GP were evaluated, and the predictive value of phosphoglycerate kinase 1 (PGK1) immunostained in surgical specimens was investigated for treatment outcomes in 1st- and 2nd-line chemotherapy. GP was associated with an objective response rate of 35.8% and a median overall survival duration of 12.3 months. Multivariate analysis showed that PS2 and 1st- and 2nd-line non-response are independent predictors of worse progression-free survival and that PS2 and 1st-line non-response are independent predictors of worse overall survival. Adverse events were manageable, and no therapy-related deaths occurred. Non-response rates to 1st-line chemotherapy were significantly higher in patients with a high expression of PGK1 in the nucleus than in those with low expression (p = 0.006). Our study demonstrates the efficacy and tolerability of 2nd-line GP for patients with aUC who are refractory to platinum-based chemotherapy. Moreover, PGK1 in the nucleus was predictive values for resistance to platinum-based chemotherapy in aUC.
- Published
- 2022
- Full Text
- View/download PDF